SC 13G | 2024-04-10 | STATE STREET CORP | C4 Therapeutics, Inc. | - | 10.4% | EDGAR |
SC 13G/A | 2024-03-08 | WASATCH ADVISORS LP | C4 Therapeutics, Inc. | - | - | EDGAR |
SC 13G/A | 2024-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | C4 Therapeutics, Inc. | 2,558,480 | 5.2% | EDGAR |
SC 13G/A | 2024-02-14 | RTW INVESTMENTS, LP | C4 Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2024-02-14 | Lynx1 Capital Management LP | C4 Therapeutics, Inc. | 3,134,396 | 6.4% | EDGAR |
SC 13G/A | 2024-02-09 | WASATCH ADVISORS LP | C4 Therapeutics, Inc. | - | - | EDGAR |
SC 13G | 2024-02-05 | Soleus Capital Master Fund, L.P. | C4 Therapeutics, Inc. | 2,555,996 | 5.2% | EDGAR |
SC 13G/A | 2024-02-02 | Soleus Capital Master Fund, L.P. | C4 Therapeutics, Inc. | 1,835,996 | 3.7% | EDGAR |
SC 13G | 2024-01-12 | Betta Investment (Hong Kong) Ltd. | C4 Therapeutics, Inc. | 5,567,928 | 8.1% | EDGAR |
SC 13G | 2024-01-04 | Point72 Asset Management, L.P. | C4 Therapeutics, Inc. | 2,312,059 | 4.7% | EDGAR |
SC 13G | 2023-12-26 | RA CAPITAL MANAGEMENT, L.P. | C4 Therapeutics, Inc. | 4,878,000 | 9.9% | EDGAR |
SC 13G | 2023-12-22 | COMMODORE CAPITAL LP | C4 Therapeutics, Inc. | 3,800,000 | 7.7% | EDGAR |
SC 13G | 2023-11-13 | Lynx1 Capital Management LP | C4 Therapeutics, Inc. | 3,122,219 | 6.3% | EDGAR |
SC 13G | 2023-07-25 | MILLENNIUM MANAGEMENT LLC | C4 Therapeutics, Inc. | 2,370,504 | 4.8% | EDGAR |
SC 13G/A | 2023-07-07 | BlackRock Inc. | C4 Therapeutics, Inc. | 2,086,563 | 4.3% | EDGAR |
SC 13G/A | 2023-06-12 | ArrowMark Colorado Holdings LLC | C4 Therapeutics, Inc. | 1,493,450 | 3.0% | EDGAR |
SC 13G | 2023-04-14 | Soleus Capital Master Fund, L.P. | C4 Therapeutics, Inc. | 2,462,020 | 5.0% | EDGAR |
SC 13G/A | 2023-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | C4 Therapeutics, Inc. | 2,925,253 | 6.0% | EDGAR |
SC 13G/A | 2023-02-14 | RTW INVESTMENTS, LP | C4 Therapeutics, Inc. | 2,819,472 | 5.8% | EDGAR |
SC 13G | 2023-02-14 | ArrowMark Colorado Holdings LLC | C4 Therapeutics, Inc. | 5,802,871 | 11.8% | EDGAR |